Eleven Biotherapeutics Inc (NASDAQ:EBIO) gapped up before the market opened on Wednesday . The stock had previously closed at $0.93, but opened at $0.93. Eleven Biotherapeutics shares last traded at $0.91, with a volume of 1102870 shares.
Eleven Biotherapeutics (NASDAQ:EBIO) last released its earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter.
Several hedge funds have recently made changes to their positions in EBIO. Municipal Employees Retirement System of Michigan acquired a new position in shares of Eleven Biotherapeutics during the 3rd quarter valued at about $382,000. Virtu KCG Holdings LLC acquired a new position in shares of Eleven Biotherapeutics during the 2nd quarter valued at about $175,000. Finally, Vanguard Group Inc. boosted its position in shares of Eleven Biotherapeutics by 17.4% during the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 30,600 shares during the last quarter. 3.84% of the stock is currently owned by hedge funds and other institutional investors.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.